StocksMedium•9 November 2026•
1 min read
Ionis Pharmaceuticals Shares Drop After 50% Cut to Key Drug Revenue Guidance
Key Facts
1Ionis Pharmaceuticals slashed its full-year revenue guidance for one of its flagship drugs by 50%.
2The company's shares fell as the guidance cut overshadowed third-quarter earnings that had otherwise beaten estimates.
Ionis Pharmaceuticals slashed its full-year revenue guidance for one of its flagship drugs by 50%. Barron's reported that the company's shares fell as the guidance cut overshadowed third-quarter earnings that had otherwise beaten estimates.
IONS closed at $39.42 on November 6, 2026, after reaching a day high of $40 and a low of $38.53. The significant reduction in the outlook for a core product drove negative sentiment, outweighing the reported financial beat for the quarter.